23214-92-8 | Doxorubicin (DOX)

Chemical type

• Anthracycline anticancer drug
• Positively charged chemotherapeutic agent
• Fluorescent small molecule

^[1]

• Anthracycline antibiotic
• Anthraquinone derivative

^[2]

• Anthracycline chemotherapy drug

^[3]

Key properties

• Protonated amine group enables electrostatic binding to carboxylate-containing carriers
• Intercalates DNA, leading to cytotoxicity primarily in cancer cells
• Releases minimally (13.9% in 12 h) at physiological pH without GSH, but rapidly (84% in 12 h) under acidic/reducing conditions
• IC₅₀ of 0.08 µM in MCF-7 cells when loaded in nanogel (1.6-fold more potent than free DOX)

^[1]

• Widely used chemotherapeutic agent
• Causes cumulative dose-dependent cardiotoxicity
• Induces mitochondrial dysfunction and oxidative stress

^[2]

• DNA intercalator and topoisomerase II inhibitor
• Well-known apoptosis inducer

^[3]

• Model drug for evaluating stimuli-responsive delivery systems
• Chemotherapy for breast cancer and other malignancies
• Fluorescent probe for tracking intracellular localization and release

^[1]

• First-choice antitumor drug for malignant solid tumors and acute lymphomas

^[2]

• Positive control for apoptosis induction in cancer cell studies

^[3]

Classification by use

• Anticancer therapeutics in nanocarrier formulations
• Chemicals used in controlled release studies
• Positively charged cargos for electrostatic loading in drug delivery systems

^[1]

• Chemotherapeutic agents
• Chemicals inducing experimental cardiotoxicity/disease models

^[2]

• Apoptosis-inducing agents

^[3]

A trustworthy factory and manufacturer

1. [Cite:1] Nanogels crosslinked with a novel selenocystine-based linker for triple-stimuli-responsive drug delivery, Chemical Engineering Journal Advances, Volume 25, March 2026, 100959
2. [Cite:2] ANKRD1 knockdown attenuates doxorubicin-induced dilated cardiomyopathy by regulating mitochondrial dysfunction and oxidative stress through activation of the AMPK/AKT/mTOR pathway, Electronic Journal of Biotechnology, Volume 79, January 2026, 100696
3. [Cite:3] PHA-665752’s Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells, Int. J. Mol. Sci., 2024, 25(5), 2871